The company is focused on the discovery, development and commercialization of monoclonal antibodies
Scientific Advisory Board
Members of MediaPharma's Scientific Advisory Board include:
Fabio Malavasi
Professor of Medical Genetics at the University of Turin Medical School, Turin, Italy
Dr. Malavasi obtained an M.D. Degree at the Medical School, University of Ferrara, Italy.
During 1978-1982 he was Visiting Scientist at the Dept. of Medical Genetics, Mount Sinai School of Medicine, New York, N.Y., at Basel Institute for Immunology, Basel, Switzerland, and at the Sloan-Kettering Cancer Center, New York, N.Y.
In 1982 Prof. Malavasi was nominated Associate Professor of Cell Biology, University of Torino Medical School, Italy.
In 1985 he was Visiting Scientist, Lab of Cellular and Molecular Biology, Beth Israel Hospital, New York, N.Y.
In 1994 he was nominated Professor of Cell Biology at the University of Ancona Medical School, Ancona, Italy.
Giampaolo Tortora
Professor of Medical Oncology and Head of the Clinical Unit and the Laboratories of Molecular Cancer Therapy at the Medical School of the University of Naples Federico II.
Dr. Tortora obtained an M.D. Degree, a Specialty in Oncology and a Ph.D. in Molecular Biology and Pathology, completing his training for 5 years at the National Cancer Institute in Bethesda, MD, USA.
His expertise is in the study and development, from preclinical studies to clinical setting, of drugs targeting growth factors receptors and signal transducers.
He received several awards for his work.
Silvia Trasciatti
Silvia Trasciatti graduated in Biological Sciences at the University of Pisa, Italy, in 1986, then proceeded with a PhD in Biotechnology at the University of Milan, and a PhD in Nutritional Science at the University of Firenze, Italy.
The later acquisition of Istituto Gentili by Merck & Co gave birth to the spin-off company Abiogen Pharma, where
Dr Trasciatti started a fruitful collaboration with Universities and research institutes in the field of oncology,
coordinating the development of monoclonal antibodies and somatic cell therapies, from discovery to phase II clinical trials.
As Director of the Research & Development Division in Abiogen Pharma, Dr Trasciatti is also deeply involved in licencing and business development, as well as strategic planning.
She has a broad technical experience in the fields of pharmacology, toxicology and molecular biology, as well as knowledge of GLP, GCP and International Regulations for drug approval (ICH, FDA, EMEA, OECD) and patenting.
Her main scientific fields of interest and experience are: Bone disease, wound healing, cartilage metabolism, monoclonal antibodies, biomaterials, cancer, immunotherapy, biotechnology, science of complex systems.
Axel Ullrich
Professor Axel Ullrich was trained as a biochemist at the University of Tuebingen (Germany) and earned a Ph.D. in Heidelberg in Molecular Genetics in 1975.
After a postdoctoral tenure at the University of California, San Francisco, he joined Genentech in 1978.
His work in the field of signal transduction research has elucidated major fundamental molecular mechanisms that govern the physiology of normal cells and allowed insights into patho-physiological mechanisms of major human diseases.
For over 25 years Professor Ullrich has been a leader in gene-technology, translating basic science discoveries into medical applications. This led in the mid eighties to the development of Humulin (human Insulin for the treatment of diabetes; Lilly), the first therapeutic agent to be developed through gene-based technology and the first biotechnology product ever.
Another biotech product that is based on Professor Ullrich's work is Herceptin, the first target-directed,gene discovery-based cancer therapy for the treatment of metastatic breast carcinoma (Genentech/Roche).
Another cancer drug, SU11248/SUTENT, was conceived on the basis of discoveries of Professor Axel Ullrich at the Max Planck Institute of Biochemistry and developed by SUGEN/Pharmacia and Pfizer.
It was recently approved by the FDA (1/2006) and the EMEA (7/2006) for the treatment of Gastro Intestinal Stromal Tumors and Renal Cell Carcinoma (Pfizer).
Since 1988, Professor Ullrich has been Director of the Department of Molecular Biology at the Max-Planck-Institute of Biochemistry in Martinsried and in addition since 2004 he is Research Director of the Singapore OncoGenome Project.
He is one of the ten most cited scientists over the past 25 years worldwide.
Professor Ullrich has been a leader in international Biotechnology development with activities stretching from Germany to the USA, Singapore and Australia.
He is cofounder of four Biotech companies - SUGEN Inc. (USA), Axxima Pharmaceuticals AG (Germany), U3 Pharma AG (Germany) and Kinaxo (Germany).
From left to right:
Giampaolo Tortora, Axel Ullrich, Silvia Trasciatti, Fabio Malavasi
Last updated: 27/04/2010 15:03
Tag Cloud
Subscribe to Rss Feed
ShareMediaPharma s.r.l. P.IVA.: IT 02282760699 | Rea di Chieti: 166532
The information provided on www.mediapharma.it is designed to complement, not replace, the relationship between a patient and his/her own physician.
